A new review article titled „Current Perspectives on the Treatment of Refractory or Recurrent Classical Hodgkin Lymphoma in Brazil: Harmonizing Efficacy, Safety, and Tolerance“ was published in Oncotargets Volume 14 on December 12, 2023.
Classic Hodgkin lymphoma (cHL), which accounts for 90-95% of all Hodgkin lymphoma cases, is the most common cancer in adolescents and the most common lymphoma in adolescents and young adults. Despite significant improvements in recent decades and the overall responsiveness of cHL to first-line chemotherapy, about 10-15% of patients suffer from refractory disease, which either does not respond to such therapy or progresses after an initial partial response.
For patients with refractory or recurrent disease, standard treatment until recently mainly consisted of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem cell transplantation. However, an improved understanding of cHL pathobiology in conjunction with the introduction of new drugs has significantly altered the treatment landscape in the last decade. Although refractory or recurrent cHL remains a challenge, the therapeutic landscape is undergoing profound changes spurred by novel agents, particularly Brentuximab Vedotin and immunotherapy.
In this new review, researchers Flávia Dias Xavier, Danielle Leão Cordeiro de Farias, Abrahão Elias Hallack Neto, Glaciano Nogueira Ribeiro, Marco Aurelio Salvino de Araujo, Thiago Xavier Carneiro, and Otavio Cesar Carvalho Guimarães Baiocchi from various institutions in Brazil discuss the main treatment options for adult patients with refractory or recurrent cHL, with a particular focus on the Brazilian healthcare system, which is constrained by inherent peculiarities.
„In attempting to harmonize efficacy, safety, and tolerance, practicing physicians must rely on clinical trial data and real-world evidence in guiding treatment decisions for refractory or recurrent cHL, utilizing their own perspectives and experience as well as patient characteristics and previous therapies,“ the researchers state.
Xavier, L., et al. (2023). Current Perspectives on the Treatment of Refractory or Recurrent Classical Hodgkin Lymphoma in Brazil: Harmonizing Efficacy, Safety, and Tolerance. Oncotarget. doi.org/10.18632/oncotarget.28541.